News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Neurogen Says Insomnia Drug Safe In Phase I Trial
December 8, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Dec 8 (Reuters) - Neurogen Corp. (NRGN.O: Quote, Profile, Research) on Thursday said the results of its Phase I multiple ascending dose trial for insomnia drug NG2-73 showed that the compound was safe and well tolerated.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
MORE ON THIS TOPIC
Spinal muscular atrophy
Roche Ends Run for Muscular Atrophy Drug, Leaving Door Open for Competitors
March 20, 2026
·
2 min read
·
Tristan Manalac
FDA
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure
March 19, 2026
·
2 min read
·
Annalee Armstrong
Diabetes
Lilly Builds Differentiated Profile for Triple-G Agonist With Late-Stage Diabetes Data
March 19, 2026
·
2 min read
·
Tristan Manalac
Layoffs
Gossamer Nearly Halves Workforce in Savings Push After Late-Stage Hypertension Fail
March 19, 2026
·
2 min read
·
Tristan Manalac
